Newsletter registration

Austria.
Dynamic Business Location.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • How to Set up a company in Austria

    28.09.2017, Bratislava, Slovakia

Austria Map

Find the perfect location for your company

Inspite of higher labor costs, the productivity of Siemens Villach is comparable to other Siemens susidiaries in Japan or the USA.

Siemens Austria

Logo
More testimonials

news from the business location Austria

Austria supports researchers from all over the world with grants of up to EUR 500,000

Austria aims at further strengthening its dynamic innovation landscape. The Alpine Republic has created a comprehensive funding program entitled “Spin-off Austria”. The new fellowship initiative is designed to appeal to scientists, providing them with up to EUR 500,000 in support to further convert their research results and findings into specific business ideas.

Tax Incentives for Companies in Business Location Austria

It is a challenge for companies to learn their way around the complex Austrian tax landscape. As a result, they often forego tax advantages they could claim. Business Location Austria offers a series of tax benefits for holding companies, tax groups and research-intensive companies.

More news All blog posts